Trial Information

Summary: Severe Liver Fibrosis due to Hepatitis C

A phase II, double blind, randomized, placebo-controlled, multicenter, study of the safety and anti-fibrotic efficacy of interferon-gamma 1b (IFN-Y 1b) in patients with severe liver fibrosis or compensated cirrhosis due to Hepatitis C.

You may be eligible to participate in the above clinical research study if you:

• Have chronic hepatitis C infection
• Are between the ages of 18 and 75 years of age
• Have not benefited from prior treatment with interferon-alpha-based therapies or combinations of therapies
• Are willing to undergo a liver biopsy
• Have not been treated with interferon-a-based therapy within the past 12 months.
• Do not have any of the following: autoimmune hepatitis, chronic hepatitis B, Wilson’s disease, drug-or toxin induced liver disease, alcohol-related liver disease, rheumatoid arthritis, systemic lupus, autoimmune thyroid disease, and are not HIV positive.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:19 AM